Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Mr. Kender added, "The potential of epigenomic controllers to modulate nearly any human gene unlocks tremendous opportunities for transformative change across a broad range of diseases. I look forward to working with this accomplished board and management team to help realize the full potential of the OMEGA platform and precision epigenomic control." Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cu ...